Immutep
IPOCutting-edge immunotherapies to fight cancer and autoimmune disease
Public · $5.2M raised
- Business Model
- B2B
- Website
- immutep.com
- Total Funding
- $5.2M
- Last Round
- Venture RoundJun 2024
- Rounds
- 4
- Type
- Public
- Ticker
- IMMP · NASDAQ
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
About
Immutep develops immunotherapies designed to stimulate or suppress the immune system against cancer and autoimmune diseases. Its research builds on the discovery of Lymphocyte Activation Gene-3 and spans therapies that activate antigen-presenting cells, block inhibitory signaling on T cells, or restore immune balance. The company's principal programs include eftilagimod alfa for oncology and IMP761 for autoimmune disease, supported by additional clinical and early-research candidates.
Summary
Immutep is a Biotech company. It has raised $5.2M in total across 4 rounds, most recently a Venture Round in Jun 2024. Investors include Altium Capital.
Funding History
Jun 2024
Sign up to see all 4 events
Funding: Venture Round. Amounts, valuations, and investors where available.
Investors
Similar Companies
Asymchem is a pharmaceutical CDMO providing R&D, chemistry, manufacturing, and control services t...
San Diego-based clinical stage biopharmaceutical company focused on the development of small mole...
Altos Labs combines academic science and industry development to create medicines that restore ce...
BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/immutep"><img src="https://indexed.vc/api/badge/company/immutep" alt="Immutep on Indexed.vc" width="260" height="76" /></a>